Preferred Label : miglustat;
MeSH note : a glucosylceramide synthase inhibitor;
CISMeF synonym : OGT 918; SC 48334; zavesca;
MeSH synonym : n-butyldeoxynojirimycin; n-butyl deoxynojirimycin; N-(n-butyl)deoxy-nojirimycin; N-(n-butyl)deoxynojirimycin; butyldeoxynojirimycin;
MeSH hyponym : SC-48334; OGT-918;
Is substance : O;
UNII : ADN3S497AZ;
InChIKey : UQRORFVVSGFNRO-UTINFBMNSA-N;
Origin ID : C059896;
UMLS CUI : C1321596;
ATC code(s)
Currated CISMeF NLP mapping
MeSH indexing information
MeSH term(s) associated for indexing
Pharmacological action(s)
Record concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://ansm.sante.fr/tableau-acces-derogatoire/miglustat
2023
false
false
false
France
French
miglustat
miglustat
drug information
drug information
---
https://www.has-sante.fr/jcms/p_3470276/fr/pombiliti-cipaglucosidase-alfa-/-opfolda-miglustat-forme-tardive-de-la-maladie-de-pompe
2023
false
false
false
France
Glycogen storage disease type II late onset (disorder)
Glycogen storage disease type II late onset (disorder)
Glycogen storage disease type II late onset (disorder)
treatment outcome
treatment outcome
treatment outcome
insurance, health, reimbursement
insurance, health, reimbursement
insurance, health, reimbursement
drug therapy, combination
drug therapy, combination
drug therapy, combination
enzyme replacement therapy
enzyme replacement therapy
enzyme replacement therapy
adult
adult
adult
cipaglucosidase alfa
cipaglucosidase alfa
cipaglucosidase alfa
infusions, intravenous
infusions, intravenous
infusions, intravenous
administration, oral
administration, oral
administration, oral
miglustat
miglustat
miglustat
evaluation of the transparency committee
evaluation of the transparency committee
evaluation of the transparency committee
miglustat
miglustat
miglustat
glycogen storage disease type ii
glycogen storage disease type ii
glycogen storage disease type ii
Cipaglucosidase Alfa
Cipaglucosidase Alfa
Cipaglucosidase Alfa
---
https://www.ema.europa.eu/en/medicines/human/EPAR/opfolda
2023
false
false
false
Netherlands
French
English
treatment outcome
treatment outcome
treatment outcome
syndication feed
syndication feed
syndication feed
summary of product characteristics
summary of product characteristics
summary of product characteristics
package leaflet
package leaflet
package leaflet
drug evaluation
drug evaluation
drug evaluation
miglustat
miglustat
miglustat
miglustat
miglustat
miglustat
miglustat
miglustat
miglustat
drug approval
drug approval
drug approval
europe
europe
europe
adult
adult
adult
Glycogen storage disease due to acid maltase deficiency, late-onset
Glycogen storage disease due to acid maltase deficiency, late-onset
Glycogen storage disease due to acid maltase deficiency, late-onset
adult glycogen storage disease type II
adult glycogen storage disease type II
adult glycogen storage disease type II
drug therapy, combination
drug therapy, combination
drug therapy, combination
Cipaglucosidase Alfa
Cipaglucosidase Alfa
Cipaglucosidase Alfa
administration, oral
administration, oral
administration, oral
capsules
capsules
capsules
aged
aged
aged
food-drug interactions
food-drug interactions
food-drug interactions
pregnancy
pregnancy
pregnancy
breast feeding
breast feeding
breast feeding
drug evaluation, preclinical
drug evaluation, preclinical
drug evaluation, preclinical
---
https://www.has-sante.fr/jcms/p_3456825/fr/pombiliti-cipaglucosidase-alfa-opfolda-miglustat-en-association-forme-tardive-maladie-de-pompe
2023
false
false
false
France
Cipaglucosidase Alfa
Cipaglucosidase Alfa
Cipaglucosidase Alfa
cipaglucosidase alfa
cipaglucosidase alfa
cipaglucosidase alfa
Glycogen storage disease type II late onset (disorder)
Glycogen storage disease type II late onset (disorder)
Glycogen storage disease type II late onset (disorder)
miglustat
miglustat
miglustat
treatment outcome
treatment outcome
treatment outcome
insurance, health, reimbursement
insurance, health, reimbursement
insurance, health, reimbursement
evaluation of the transparency committee
evaluation of the transparency committee
evaluation of the transparency committee
miglustat
miglustat
miglustat
drug therapy, combination
drug therapy, combination
drug therapy, combination
glycogen storage disease type ii
glycogen storage disease type ii
glycogen storage disease type ii
---
https://www.has-sante.fr/jcms/p_3184914/fr/miglustat-dipharma
2020
false
false
false
France
drugs, generic
drugs, generic
evaluation of the transparency committee
evaluation of the transparency committee
miglustat
miglustat
1-Deoxynojirimycin
1-Deoxynojirimycin
---
https://www.ema.europa.eu/en/medicines/human/EPAR/miglustat-dipharma
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
adult
drugs, generic
drug approval
europe
miglustat
miglustat
gaucher disease, type 1
administration, oral
enzyme inhibitors
enzyme inhibitors
ceramide glucosyltransferase
drug interactions
pregnancy
breast feeding
miglustat
gaucher disease
1-Deoxynojirimycin
1-Deoxynojirimycin
1-Deoxynojirimycin
glucosyltransferases
---
https://www.has-sante.fr/jcms/p_3122215/fr/miglustat-accord
2019
false
false
false
France
miglustat
Niemann-Pick disease, type C
adult
treatment outcome
insurance, health, reimbursement
drugs, generic
administration, oral
child
adolescent
evaluation of the transparency committee
miglustat
1-Deoxynojirimycin
---
https://www.has-sante.fr/jcms/p_3104691/fr/yargesa
2019
false
false
false
France
drugs, generic
drugs, generic
miglustat
miglustat
evaluation of the transparency committee
evaluation of the transparency committee
1-Deoxynojirimycin
1-Deoxynojirimycin
1-Deoxynojirimycin
1-Deoxynojirimycin
---
https://www.has-sante.fr/jcms/p_3084023/fr/miglustat-dipharma
2019
false
false
false
France
evaluation of the transparency committee
miglustat
1-Deoxynojirimycin
---
https://www.has-sante.fr/portail/jcms/c_2856028/fr/miglustat-gen-orph
2018
false
false
false
false
France
French
evaluation of the transparency committee
evaluation of the transparency committee
miglustat
miglustat
1-Deoxynojirimycin
1-Deoxynojirimycin
---
https://www.has-sante.fr/portail/jcms/c_2891311/fr/miglustat-accord
2018
false
false
false
France
evaluation of the transparency committee
miglustat
1-Deoxynojirimycin
---
https://www.ema.europa.eu/medicines/human/EPAR/miglustat-genorph
2017
false
United Kingdom
French
English
syndication feed
drugs, generic
miglustat
Product containing precisely miglustat 100 milligram/1 each conventional release oral
capsule (clinical drug)
gaucher disease, type 1
enzyme inhibitors
europe
enzyme inhibitors
1-Deoxynojirimycin
gaucher disease
administration, oral
adult
treatment outcome
drug interactions
pregnancy
breast feeding
drug approval
miglustat
miglustat
ceramide glucosyltransferase
glucosyltransferases
1-Deoxynojirimycin
glucosyltransferases
package leaflet
drug evaluation
summary of product characteristics
Gaucher disease type 1
---
https://www.ema.europa.eu/medicines/human/EPAR/Yargesa
2017
false
United Kingdom
French
English
syndication feed
drugs, generic
Product containing precisely miglustat 100 milligram/1 each conventional release oral
capsule (clinical drug)
Product containing miglustat (medicinal product)
miglustat
gaucher disease, type 1
enzyme inhibitors
1-Deoxynojirimycin
gaucher disease
administration, oral
adult
treatment outcome
drug interactions
pregnancy
breast feeding
drug approval
miglustat
miglustat
ceramide glucosyltransferase
glucosyltransferases
1-Deoxynojirimycin
package leaflet
drug evaluation
summary of product characteristics
Gaucher disease type 1
---
Mise à disposition d'un générique de ZAVESCA
http://www.has-sante.fr/portail/jcms/c_2607073/fr/miglustat-bluefish
2016
false
France
French
English
Product containing precisely miglustat 100 milligram/1 each conventional release oral
capsule (clinical drug)
Product containing precisely miglustat 100 milligram/1 each conventional release oral
capsule (clinical drug)
Product containing precisely miglustat 100 milligram/1 each conventional release oral
capsule (clinical drug)
drugs, generic
drugs, generic
drugs, generic
gaucher disease, type 1
gaucher disease, type 1
gaucher disease, type 1
miglustat
miglustat
miglustat
administration, oral
administration, oral
administration, oral
miglustat
miglustat
miglustat
adult
adult
adult
child
child
child
1-Deoxynojirimycin
1-Deoxynojirimycin
1-Deoxynojirimycin
enzyme inhibitors
enzyme inhibitors
enzyme inhibitors
treatment outcome
treatment outcome
treatment outcome
evaluation of the transparency committee
evaluation of the transparency committee
evaluation of the transparency committee
gaucher disease
gaucher disease
gaucher disease
---
https://www.ema.europa.eu/medicines/human/EPAR/Zavesca
2012
false
United Kingdom
French
English
syndication feed
syndication feed
syndication feed
enzyme inhibitors
enzyme inhibitors
enzyme inhibitors
1-Deoxynojirimycin
1-Deoxynojirimycin
1-Deoxynojirimycin
gaucher disease
gaucher disease
gaucher disease
capsules
capsules
capsules
administration, oral
administration, oral
administration, oral
orphan drug production
orphan drug production
orphan drug production
adult
adult
adult
treatment outcome
treatment outcome
treatment outcome
drug interactions
drug interactions
drug interactions
pregnancy
pregnancy
pregnancy
breast feeding
breast feeding
breast feeding
drug approval
drug approval
drug approval
drug labeling
drug labeling
drug labeling
miglustat
miglustat
miglustat
miglustat
miglustat
miglustat
ceramide glucosyltransferase
ceramide glucosyltransferase
ceramide glucosyltransferase
glucosyltransferases
glucosyltransferases
glucosyltransferases
1-Deoxynojirimycin
1-Deoxynojirimycin
1-Deoxynojirimycin
glucosyltransferases
glucosyltransferases
glucosyltransferases
package leaflet
package leaflet
package leaflet
drug evaluation
drug evaluation
drug evaluation
summary of product characteristics
summary of product characteristics
summary of product characteristics
Gaucher disease type 1
Gaucher disease type 1
Gaucher disease type 1
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-01/zavesca_-_ct-7042.pdf
http://www.has-sante.fr/portail/jcms/c_946087/zavesca-miglustat-inhibiteur-de-la-glucosylceramide-synthetase
2009
France
French
miglustat
miglustat
miglustat
1-Deoxynojirimycin
1-Deoxynojirimycin
1-Deoxynojirimycin
orphan drug production
orphan drug production
orphan drug production
enzyme inhibitors
enzyme inhibitors
enzyme inhibitors
ceramide glucosyltransferase
ceramide glucosyltransferase
ceramide glucosyltransferase
glucosyltransferases
glucosyltransferases
Niemann-Pick disease, type C
Niemann-Pick disease, type C
miglustat
miglustat
administration, oral
administration, oral
adult
adult
child
child
treatment outcome
treatment outcome
miglustat
miglustat
enzyme inhibitors
enzyme inhibitors
1-Deoxynojirimycin
1-Deoxynojirimycin
glucosyltransferases
glucosyltransferases
guidelines for drug use
guidelines for drug use
guidelines for drug use
evaluation of the transparency committee
evaluation of the transparency committee
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-02/zavesca_ct_7042.pdf
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-01/zavesca_-_ct-7042.pdf
http://www.has-sante.fr/portail/jcms/c_905044/zavesca
2009
false
France
French
English
rare diseases
rare diseases
miglustat
miglustat
administration, oral
administration, oral
orphan drug production
orphan drug production
miglustat
miglustat
Niemann-Pick disease, type C
Niemann-Pick disease, type C
adult
adult
child
child
1-Deoxynojirimycin
1-Deoxynojirimycin
enzyme inhibitors
enzyme inhibitors
treatment outcome
treatment outcome
evaluation of the transparency committee
evaluation of the transparency committee
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/display.jsp?id=c_399915
http://www.has-sante.fr/portail/upload/docs/application/pdf/ct031484.pdf
2003
France
French
capsules
capsules
capsules
orphan drug production
orphan drug production
orphan drug production
gaucher disease
gaucher disease
gaucher disease
glucosyltransferases
glucosyltransferases
glucosyltransferases
ceramide glucosyltransferase
ceramide glucosyltransferase
ceramide glucosyltransferase
miglustat
miglustat
miglustat
administration, oral
administration, oral
administration, oral
treatment outcome
treatment outcome
treatment outcome
miglustat
miglustat
miglustat
1-Deoxynojirimycin
1-Deoxynojirimycin
1-Deoxynojirimycin
enzyme inhibitors
enzyme inhibitors
enzyme inhibitors
glucosyltransferases
glucosyltransferases
glucosyltransferases
evaluation of the transparency committee
evaluation of the transparency committee
evaluation of the transparency committee
---